158 related articles for article (PubMed ID: 36656871)
21. Cost-utility analysis of four WHO-recommended sofosbuvir-based regimens for the treatment of chronic hepatitis C in sub-Saharan Africa.
Boyer S; Baudoin M; Nishimwe ML; Santos M; Lemoine M; Maradan G; Sylla B; Kouanfack C; Carrieri P; Mourad A; Rouveau N; Moh R; Seydi M; Attia A; Woode ME; Lacombe K
BMC Health Serv Res; 2022 Mar; 22(1):303. PubMed ID: 35248039
[TBL] [Abstract][Full Text] [Related]
22. Patient Out-of-Pocket Costs Following the Availability of Biosimilar Versions of Infliximab.
Feng K; Kesselheim AS; Russo M; Rome BN
Clin Pharmacol Ther; 2023 Jan; 113(1):90-97. PubMed ID: 36227630
[TBL] [Abstract][Full Text] [Related]
23. Does a One-Size-Fits-All Cost-Sharing Approach Incentivize Appropriate Medication Use? A Roundtable on the Fairness and Ethics Associated with Variable Cost Sharing.
Graff JS; Shih C; Barker T; Dieguez G; Larson C; Sherman H; Dubois RW
J Manag Care Spec Pharm; 2017 Jun; 23(6):621-627. PubMed ID: 28530519
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness, Safety, and Adherence to Treatment of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Real Practice.
Gayoso-Rey M; Díaz-Trastoy O; Romero-Ventosa EY; García-Beloso N; González-Freire L; Lorenzo-Lorenzo K; Mantiñán-Gil B; Palmeiro-Carballeira R; Bravo-Amaro M; López-Gil-Otero MDM; Martínez-Reglero C; Crespo-Diz C; Fernández-Catalina P; Piñeiro Corrales G
Clin Ther; 2021 Apr; 43(4):e111-e121. PubMed ID: 33712271
[TBL] [Abstract][Full Text] [Related]
25. Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter?
Curkendall S; Patel V; Gleeson M; Campbell RS; Zagari M; Dubois R
Arthritis Rheum; 2008 Oct; 59(10):1519-26. PubMed ID: 18821651
[TBL] [Abstract][Full Text] [Related]
26. Potential impact of pharmaceutical industry rebates on medication adherence.
Zullig LL; Granger BB; Vilme H; Oakes MM; Bosworth HB
Am J Manag Care; 2019 May; 25(5):e135-e137. PubMed ID: 31120709
[TBL] [Abstract][Full Text] [Related]
27. Real-world cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal coverage scheme of Punjab state in India.
Chugh Y; Dhiman RK; Premkumar M; Prinja S; Singh Grover G; Bahuguna P
PLoS One; 2019; 14(8):e0221769. PubMed ID: 31465503
[TBL] [Abstract][Full Text] [Related]
28. Out-of-pocket cost by cancer stage at diagnosis in commercially insured patients in the United States.
McGarvey N; Gitlin M; Fadli E; Chung KC
J Med Econ; 2023; 26(1):1318-1329. PubMed ID: 37907436
[TBL] [Abstract][Full Text] [Related]
29. Trends in Prices of Popular Brand-Name Prescription Drugs in the United States.
Wineinger NE; Zhang Y; Topol EJ
JAMA Netw Open; 2019 May; 2(5):e194791. PubMed ID: 31150077
[TBL] [Abstract][Full Text] [Related]
30. Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data.
Chen GF; Wei L; Chen J; Duan ZP; Dou XG; Xie Q; Zhang WH; Lu LG; Fan JG; Cheng J; Wang GQ; Ren H; Wang JP; Yang XX; Jia ZS; Fu QC; Wang XJ; Shang J; Zhang YX; Han Y; Du N; Shao Q; Ji D; Li F; Li B; Liu JL; Niu XX; Wang C; Wu V; Wong A; Wang YD; Hou JL; Jia JD; Zhuang H; Lau G
PLoS One; 2016; 11(6):e0155934. PubMed ID: 27276081
[TBL] [Abstract][Full Text] [Related]
31. Impact of Out-of-Pocket Costs on Prescription Fills Among New Initiators of Biologic Therapies for Rheumatoid Arthritis.
Hopson S; Saverno K; Liu LZ; AL-Sabbagh A; Orazem J; Costantino ME; Pasquale MK
J Manag Care Spec Pharm; 2016 Feb; 22(2):122-30. PubMed ID: 27015251
[TBL] [Abstract][Full Text] [Related]
32. Cost-Effectiveness Analysis of Pan-Genotypic Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C Genotype 1 Infection in China.
Zhou HJ; Cao J; Shi H; Naidoo N; Semba S; Wang P; Fan YF; Zhu SC
Front Public Health; 2021; 9():779215. PubMed ID: 34957030
[No Abstract] [Full Text] [Related]
33. The Impact of Sharing Drug Rebates at the Point of Sale on Out-of-Pocket Payments for Enrollees in Employer-Sponsored Insurance.
Ding Y; Miller GE
Value Health; 2023 Feb; 26(2):226-233. PubMed ID: 36114087
[TBL] [Abstract][Full Text] [Related]
34. Cost burden of hepatitis C virus treatment in commercially insured patients.
Lu CY; Ross-Degnan D; Zhang F; LeCates R; Lupton C; Sherman M; Wagner A
Am J Manag Care; 2019 Dec; 25(12):e379-e387. PubMed ID: 31860232
[TBL] [Abstract][Full Text] [Related]
35. Effect of Out-of-Pocket Cost on Medication Initiation, Adherence, and Persistence among Patients with Type 2 Diabetes: The Diabetes Study of Northern California (DISTANCE).
Karter AJ; Parker MM; Solomon MD; Lyles CR; Adams AS; Moffet HH; Reed ME
Health Serv Res; 2018 Apr; 53(2):1227-1247. PubMed ID: 28474736
[TBL] [Abstract][Full Text] [Related]
36. Impact of Patient Reimbursement Timing and Patient Out-of-Pocket Expenses on Medication Adherence in Patients Covered by Private Drug Insurance Plans.
Després F; Forget A; Kettani FZ; Blais L
J Manag Care Spec Pharm; 2016 May; 22(5):539-47. PubMed ID: 27123915
[TBL] [Abstract][Full Text] [Related]
37. Adoption of Cost Effectiveness-Driven Value-Based Formularies in Private Health Insurance from 2010 to 2013.
Brouwer ED; Basu A; Yeung K
Pharmacoeconomics; 2019 Oct; 37(10):1287-1300. PubMed ID: 31270747
[TBL] [Abstract][Full Text] [Related]
38. The Association between Type of Insurance Plan, Out-of-Pocket Cost, and Adherence to Antihypertensive Medications in Medicare Supplement Insurance Enrollees.
Zhang D; Xu J; Hall DB; Chen X; Chen M; Divers J; Wei J; Rajbhandari-Thapa J; Wright DR; Arabadjian M; Young HN
Am J Hypertens; 2024 May; ():. PubMed ID: 38727326
[TBL] [Abstract][Full Text] [Related]
39. Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment.
Nunn AS; Fonseca EM; Bastos FI; Gruskin S; Salomon JA
PLoS Med; 2007 Nov; 4(11):e305. PubMed ID: 18001145
[TBL] [Abstract][Full Text] [Related]
40. Estimates of Medicaid and Non-Medicaid Net Prices of Top-Selling Brand-name Drugs Incorporating Best Price Rebates, 2015 to 2019.
Clemans-Cope L; Epstein M; Banthin J; Kesselheim AS; Hwang TJ
JAMA Health Forum; 2023 Jan; 4(1):e225012. PubMed ID: 36637815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]